Drug General Information
Drug ID
D09QCD
Former ID
DNC009231
Drug Name
KYS-05056
Drug Type
Small molecular drug
Indication Discovery agent Investigative [529566]
Formula
C25H27N5O
Canonical SMILES
CN(C)C1=NC2=CC=CC=C2C(N1C3=CC=CC=C3)CC(=O)NCC4=CC=C(C=C<br />4)N
InChI
1S/C25H27N5O/c1-29(2)25-28-22-11-7-6-10-21(22)23(30(25)20-8-4-3-5-9-20)16-24(31)27-17-18-12-14-19(26)15-13-18/h3-15,23H,16-17,26H2,1-2H3,(H,27,31)
InChIKey
ADQNFSXMHBVQJA-UHFFFAOYSA-N
PubChem Compound ID
Target and Pathway
Target(s) Voltage-dependent T-type calcium channel alpha-1G subunit Target Info Inhibitor [529566]
KEGG Pathway MAPK signaling pathway
Calcium signaling pathway
Circadian entrainment
Type II diabetes mellitus
PANTHER Pathway Endogenous cannabinoid signaling
GABA-B receptor II signaling
Nicotine pharmacodynamics pathway
Pathway Interaction Database Regulation of nuclear beta catenin signaling and target gene transcription
PathWhiz Pathway Muscle/Heart Contraction
Reactome NCAM1 interactions
WikiPathways NCAM signaling for neurite out-growth
Nicotine Activity on Chromaffin Cells
References
Ref 529566Bioorg Med Chem Lett. 2008 Jul 15;18(14):3899-901. Epub 2008 Jun 14.T-type Ca2+ channel blockers suppress the growth of human cancer cells.
Ref 529566Bioorg Med Chem Lett. 2008 Jul 15;18(14):3899-901. Epub 2008 Jun 14.T-type Ca2+ channel blockers suppress the growth of human cancer cells.